Inflammation; MRI; Physiopathology; Treatment; Multiple sclerosis; Disease Progression; Humans; Magnetic Resonance Imaging/methods; Multiple Sclerosis/therapy; Magnetic Resonance Imaging; Medicine (all)
Abstract :
[en] Multiple sclerosis is a central nervous system autoimmune disease of the white and grey matters. Its pathophysiology is much better well known. It results from the interaction between genetic and environmental susceptibility factors. The role of EBV virus has recently been highlighted. Imaging techniques and neuropathology knowledge allow to distinguish several distinct processes responsible for focal and more diffuse inflammation. Therapeutic advances in recent years have been considerable. Different molecules and treatment sequences can be proposed to the patient with a demonstrated positive impact on the risk of disability secondary progression. Precise follow-up is a key. It requires optimal and early use of various treatments. The therapeutic choice must be guided by obtaining stabilization of the disease, both clinically and in terms of imaging, without exposing the patient to an excessive risk of side effects. Continuous and sequential treatments are available. [fr] : La sclérose en plaques est une maladie auto-immune du système nerveux central qui concerne la substance blanche mais aussi la substance grise. Sa physiopathologie est beaucoup mieux connue. Elle résulte de l’interaction entre des facteurs génétiques de susceptibilité et environnementaux. Le rôle du virus EBV a été récemment souligné. Les techniques d’imagerie et les connaissances de neuropathologie ont permis de distinguer plusieurs processus distincts responsables d’une inflammation focale, mais également plus diffuse. Les progrès thérapeutiques des dernières années sont considérables. Différentes molécules et séquences de traitements peuvent être proposées au patient avec un impact positif démontré sur le risque de progression secondaire du handicap. La précision du suivi est un élément clé de la prise en charge. Elle requiert une utilisation optimale, et surtout précoce, des différents traitements. Le choix thérapeutique doit être guidé par l’obtention d’une stabilisation de la maladie, tant sur le plan clinique qu’en imagerie, sans exposer le patient à un risque excessif d’effets secondaires négatifs. Des traitements continus et séquentiels sont disponibles.
Disciplines :
Neurology
Author, co-author :
Dive, Dominique ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Dauby, Solène ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Lommers, Emilie ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Hansen, Isabelle ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Groenendyck, Dominique ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
ERNON, Christine ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Maquet, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > > Service de neurologie
Language :
French
Title :
La sclérose en plaques : une maladie neurologique dysimmunitaire inflammatoire.
Alternative titles :
[en] Multiple sclerosis : a neurological dysimmune inflammatory disease.
Kingwell E, Marriott JJ, Jette N, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC Neurol 2013;13:128.
Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers 2018;4:43.
Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-85.
Trapp BD, Vignos M, Dudman J, et al. Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study. Lancet Neurol 2018;17:870-84.
Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015;15:545-58.
Belbasis L, Bellou V, Evangelou E, et al. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 2015;14:263-73.
Belbasis L, Bellou V, Evangelou E, Tzoulaki I. Environmental factors and risk of multiple sclerosis: Findings from meta-analyses and Mendelian randomization studies. Mult Scler 2020;26:397-404.
Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 2022;375:296-301.
Wijnands JM, Zhu F, Kingwell E, et al. Five years before multiple sclerosis onset: phenotyping the prodrome. Mult Scler 2019;25:1092-101.
Makhani N, Tremlett H. The multiple sclerosis prodrome. Nat Rev Neurol 2021;17:515-21.
Feinstein A. Multiple sclerosis and depression. Mult Scler 2011;17:1276-81.
Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009;72:800-5.
Lebrun-Frenay C, Rollot F, Mondot L, et al. Risk factors and time to clinical symptoms of multiple sclerosis among patients with radiologically isolated syndrome. JAMA Netw Open 2021;4:e2128271.
Makhani N. Treatment considerations in the radiologically isolated syndrome. Curr Treat Options Neurol 2020;22:3.
Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162-73.
Brownlee WJ, Miszkiel KA, Tur C,et al. Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. Neurology 2018;91:e1130-e4.
Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-74.
Solomon AJ, Weinshenker BG. Misdiagnosis of multiple sclerosis: frequency, causes, effects, and prevention. Curr Neurol Neurosci Rep 2013;13:403.
Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol 2021;20:762-72.
Cotsapas C, Mitrovic M, Hafler D. Multiple sclerosis. Handb Clin Neurol 2018;148:723-30.
Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med 2018;378:169-80.
Krieger SC, Cook K, De Nino S, Fletcher M. The topographical model of multiple sclerosis: a dynamic visualization of disease course. Neurol Neuroimmunol Neuroinflamm 2016;3:e279.
Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials. JAMA Neurol 2020;77:1132-40.
Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278-86.
Bevan RJ, Evans R, Griffiths L, et al. Meningeal inflammation and cortical demyelination in acute multiple sclerosis. Ann Neurol 2018;84:829-42.
Lassmann H. Pathogenic Mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol 2018;9:3116.
Machado-Santos J, Saji E, Troscher AR, et al. The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8+ T lymphocytes and B cells. Brain 2018;141:2066-82.
Calvi A, Carrasco FP, Tur C, Chard DT, Stutters J, De Angelis F, et al. Association of slowly expanding lesions on mri with disability in people with secondary progressive multiple sclerosis. Neurology 2022;98:e1783-93.
Wattjes MP, Ciccarelli O, Reich DS, et al. 2021 MAGNIMSCMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol 2021;20:653-70.
Lommers E, Guillemin C, Reuter G, et al. Voxel-Based quantitative MRI reveals spatial patterns of grey matter alteration in multiple sclerosis. Hum Brain Mapp 2021;42:1003-12.
Lommers E, Simon J, Reuter G, et al. Multiparameter MRI quantification of microstructural tissue alterations in multiple sclerosis. Neuroimage Clin 2019;23:101879.
Bruschi N, Boffa G, Inglese M. Ultra-high-field 7-T MRI in multiple sclerosis and other demyelinating diseases: from pathology to clinical practice. Eur Radiol Exp 2020;4:59.
Prosperini L, Ruggieri S, Haggiag S, et al. Prognostic Accuracy of NEDA-3 in long-term outcomes of multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2021;8:e1059.
Giffroy X, Maes N, Albert A, et al. Multimodal evoked potentials for functional quantification and prognosis in multiple sclerosis. BMC Neurol 2016;16:83.
Giffroy X, Maes N, Albert A, Maquet P,et al. Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis? Acta Neurol Belg 2017;117:53-9.
Giffroy X, Dive D, Kaux JF, et al. Is the triple stimulation technique a better quantification tool of motor dysfunction than motor evoked potentials in multiple sclerosis? Acta Neurol Belg 2018;119:47-54.
Mehmood A, Ali W, Song S, et al. Optical coherence tomography monitoring and diagnosing retinal changes in multiple sclerosis. Brain Behav 2021;11:e2302.
Disanto G, Barro C, Benkert P, et al. Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017;81:857-70.
Brown JWL, Coles A, Horakova D, et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. JAMA 2019;321:175-87.
Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol 2019;76:536-41.
Capra R, Cordioli C, Rasia S, et al. Assessing long-term prognosis improvement as a consequence of treatment pattern changes in MS. Mult Scler 2017;23:1757-61.
McKeage K. Glatiramer Acetate 40 mg/mL in relapsing-remitting multiple sclerosis: a review. CNS Drugs 2015;29:425-32.
Plosker GL. Interferon-beta-1b: a review of its use in multiple sclerosis. CNS Drugs 2011;25:67-88.
Comi G. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta. Clin Ther 2009;31:1142-57.
Scott LJ. Teriflunomide: a review in relapsing-remitting multiple sclerosis. Drugs 2019;79:875-86.
Blair HA. Dimethyl Fumarate: a review in relapsing-remitting MS. Drugs 2019;79:1965-76.
Sun Y, Yang Y, Wang Z, et al. Ozanimod for treatment of relapsing-remitting multiple sclerosis in adults: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol 2020;11:589146.
Kappos L, Fox RJ, Burcklen M, et al. Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 optimum study: a randomized clinical trial. JAMA Neurol 2021;78:558-67.
McGinley MP, Cohen JA. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. Lancet 2021;398:1184-94.
Scott LJ. Siponimod: a review in secondary progressive multiple sclerosis. CNS Drugs 2020;34:1191-200.
Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007;356:2622-9.
Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol 2021;17:37-51.
Lopez PA, Alonso R, Silva B, Carnero Contentti E. Natalizumab subcutaneous injection for the treatment of relapsing multiple sclerosis patients: a new delivery route. Mult Scler Relat Disord 2021;55:103179.
Trojano M, Ramio-Torrenta L, Grimaldi LM, et al. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis. Mult Scler 2021;27:2240-53.
Hatcher SE, Waubant E, Nourbakhsh B, et al. Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 2016;73:790-4.
Sorensen PS, Koch-Henriksen N, Petersen T, et al. Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. J Neurol 2014;261:1170-7.
Ziemssen T, Thomas K. Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. Ther Adv Neurol Disord 2017;10:343-59.
Coles AJ, Jones JL, Vermersch P, et al. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: benefit/risk following review of trial and post-marketing data. Mult Scler 2022;28:842-6.
Deeks ED. Cladribine tablets: a review in relapsing MS. CNS Drugs 2018;32:785-96.
Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 2017;376:221-34.
Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376:209-20.
Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol 2022;269:1316-34.
Sormani MP, De Rossi N, Schiavetti I, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 2021;89:780-9.
Boffa G, Massacesi L, Inglese M, et al. Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis. Neurology 2021;97:203.
Garcia-Merino A. Bruton’s tyrosine kinase inhibitors: a new generation of promising agents for multiple sclerosis therapy. Cells 2021;10:2560.
Stankiewicz JM, Weiner HL. An argument for broad use of high efficacy treatments in early multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2019;7:e636.
Villoslada P, Steinman L. New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis. Expert Opin Investig Drugs 2020;29:443-59.
Wooliscroft L, Silbermann E, Cameron M, Bourdette D. Approaches to remyelination therapies in multiple sclerosis. Curr Treat Options Neurol 2019;21:34.
